Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Domain Therapeutics
Domain Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Domain makes two acquisitions for G Protein-Coupled Receptor programme
Prestwick Chemical and Neurofit are former subsidiaries of Australia-based Bionomics
Research & Development
Domain Therapeutics adds Sylvie Ryckebusch to Board
Ryckebusch joins Domain from Merck Serono
Media
Domain Therapeutics receives $125m to assign its intellectual property
Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech
Research & Development
Domain Therapeutics and Pfizer collaborate on bioSensAll
Technology will be used to profile signaling of mutant GPCRs to accelerate validation of novel GPCR drug targets
Finance
Merck will develop Domain Therapeutics next generation adenosine receptor programs
Domain Therapeutics and Merck enter into an agreement for development of adenosine receptor antagonists in immuno-oncology
Research & Development
Domain Therapeutics closes €2m funding round
Will use money to strengthen partnerships for discovering drugs targeting GPCRs
Research & Development
Domain Therapeutics wins €933,000 grant for schizophrenia project
French GPCR specialist will lead €5.1m ATHOS project
Subscribe now